Pages that link to "Q39943622"
Jump to navigation
Jump to search
The following pages link to A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells (Q39943622):
Displaying 30 items.
- Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer (Q28264693) (← links)
- Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition (Q28829301) (← links)
- Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. (Q30931456) (← links)
- The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments (Q31107044) (← links)
- Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells (Q33576337) (← links)
- Encapsulation of poorly soluble drugs in polymer-drug conjugates: effect of dual-drug nanoformulations on cancer therapy (Q33686380) (← links)
- Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins. (Q33765280) (← links)
- ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. (Q33820676) (← links)
- Ubiquitination-Dependent Regulation of Signaling Receptors in Cancer (Q34365210) (← links)
- Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer (Q34380963) (← links)
- A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. (Q34430965) (← links)
- Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers (Q34616517) (← links)
- Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models. (Q35602561) (← links)
- Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance (Q35624814) (← links)
- ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation (Q35899955) (← links)
- Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells (Q36062148) (← links)
- Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab (Q36680209) (← links)
- p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy (Q36782465) (← links)
- Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab (Q37148772) (← links)
- Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs (Q37522017) (← links)
- Treatment of HER2-positive breast cancer: current status and future perspectives. (Q37962332) (← links)
- Diverse roles of C-terminal Hsp70-interacting protein (CHIP) in tumorigenesis (Q38173991) (← links)
- Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers (Q39448675) (← links)
- 17AAG-induced internalisation of HER2-specific Affibody molecules (Q41197997) (← links)
- Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells (Q41773399) (← links)
- The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. (Q49357108) (← links)
- Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. (Q52714930) (← links)
- HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells (Q60923414) (← links)
- Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer (Q89700506) (← links)
- Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond (Q89727324) (← links)